Pfizer’s Chantix Has Short-Term Edge, But GSK Touts OTC Patch For Long Term
This article was originally published in The Tan Sheet
Executive Summary
People using Pfizer's smoking cessation Rx drug Chantix are more likely to abstain and experience fewer withdrawal symptoms at the end of treatment than smokers who use the nicotine replacement therapy provided in GlaxoSmithKline's OTC NicoDerm CQ Clean Patch, a Pfizer-funded study shows